Circulating Tumor Cells for the Staging of Patients With Newly Diagnosed Transplant-Eligible Multiple Myeloma.
Juan-José GarcésMaría-Teresa CedenaNoemi PuigLeire BurgosJose J PerezLourdes CordonJuan A Flores-MonteroLuzalba Sanoja-FloresMaría-José CalasanzAlbert OrtiolMaría-Jesús BlanchardRafael Rios-TamayoJesús Martín-SánchezRafael Martínez-MartinezJoan BargayAnna SuredaJavier de la RubiaMiguel-Teodoro T Hernandez GarciaPaula Rodriguez-OteroJavier de la CruzAlberto OrfaoMaria-Victoria Mateos-MantecaJoaquin Martinez LopezJuan-José LahuertaLaura RosinolJoan BladeJesús San F MiguelJuan José LahuertaPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022)
Evaluation of CTCs in PB outperformed quantification of BM PCs. The detection of ≥ 0.01% CTCs could be a new risk factor in novel staging systems for patients with transplant-eligible MM.